Literature DB >> 16457640

Privileged structures as leads in medicinal chemistry.

Luca Costantino1, Daniela Barlocco.   

Abstract

Among the strategies that can lead to the discovery of new drugs, the identification and use of privileged structures, molecular fragments that are able to interact with more than one target, gained particular attention, in an attempt to find new drugs in a shorter time with respect to other strategies. These structures, that have been identified mainly by empirical observations, can target only a given protein family, or can be able to interact with more, unrelated targets. This review deals with structures not covered in recent papers on this topic, and emphasizes the importance of understanding the structure-target relationships, that confer the privileged status.

Mesh:

Substances:

Year:  2006        PMID: 16457640

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  57 in total

1.  Synthesis and diversification of 1,2,3-triazole-fused 1,4-benzodiazepine scaffolds.

Authors:  James R Donald; Stephen F Martin
Journal:  Org Lett       Date:  2011-01-28       Impact factor: 6.005

2.  Facile and unified approach to skeletally diverse, privileged scaffolds.

Authors:  James J Sahn; Justin Y Su; Stephen F Martin
Journal:  Org Lett       Date:  2011-04-22       Impact factor: 6.005

3.  Multicomponent assembly strategies for the synthesis of diverse tetrahydroisoquinoline scaffolds.

Authors:  Brett A Granger; Kyosuke Kaneda; Stephen F Martin
Journal:  Org Lett       Date:  2011-08-11       Impact factor: 6.005

4.  Application of a sequential multicomponent assembly process/huisgen cycloaddition strategy to the preparation of libraries of 1,2,3-triazole-fused 1,4-benzodiazepines.

Authors:  James R Donald; Rebekah R Wood; Stephen F Martin
Journal:  ACS Comb Sci       Date:  2012-02-01       Impact factor: 3.784

Review 5.  Natural products as sources of new drugs over the 30 years from 1981 to 2010.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2012-02-08       Impact factor: 4.050

6.  Opportunities in metabolic engineering to facilitate scalable alkaloid production.

Authors:  Effendi Leonard; Weerawat Runguphan; Sarah O'Connor; Kristala Jones Prather
Journal:  Nat Chem Biol       Date:  2009-05       Impact factor: 15.040

7.  Structure-Based Optimization of Pyridoxal 5'-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis.

Authors:  Feng Liu; Surendra Dawadi; Kimberly M Maize; Ran Dai; Sae Woong Park; Dirk Schnappinger; Barry C Finzel; Courtney C Aldrich
Journal:  J Med Chem       Date:  2017-06-22       Impact factor: 7.446

8.  Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with Indole-Containing Cap Group.

Authors:  Yingjie Zhang; Penghui Yang; C James Chou; Chunxi Liu; Xuejian Wang; Wenfang Xu
Journal:  ACS Med Chem Lett       Date:  2013-01-08       Impact factor: 4.345

9.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 10.  The role of medical structural genomics in discovering new drugs for infectious diseases.

Authors:  Wesley C Van Voorhis; Wim G J Hol; Peter J Myler; Lance J Stewart
Journal:  PLoS Comput Biol       Date:  2009-10-26       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.